RAAS Inhibitors: From Blood Pressure Control to Immune Modulation

Pharmacy
, ,
1

The renin–angiotensin–aldosterone system (RAAS) maintains blood pressure, fluid, and electrolyte balance. RAAS inhibitors like angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are standard therapies to reverse the effects of overactive RAAS which can lead to HTN, CKD, and vascular damage.

:pencil: RAAS inhibitors go far beyond blood pressure control — they are emerging as powerful immune regulators with potential roles in autoimmunity, cancer, neurodegeneration, and infectious disease.

:right_arrow: RAAS and the Immune System

  • Angiotensin II (Ang II) promotes inflammation through oxidative stress, NF-κB activation, and cytokine release.

  • RAAS receptors (AT1R, AT2R) are expressed on immune cells (macrophages, T cells, dendritic cells).

  • Overactive RAAS skews immune balance toward a proinflammatory state, contributing to autoimmunity, vascular inflammation, and fibrosis.

:right_arrow: Effects of RAAS Inhibitors on Innate Immunity

  • Macrophages:

    • RAAS inhibitors reduce pro-inflammatory M1 macrophage.

    • They promote M2 macrophages, which support tissue repair and anti-inflammatory signaling.

  • Cytokines & ROS: ACEIs/ARBs lower IL-1β, TNF-α, IL-6, and reactive oxygen species.

  • Antigen-presenting cells (APCs): They reduce MHC II and costimulatory molecule expression, lowering T-cell activation.

:right_arrow: Effects of RAAS inhibitors on Adaptive Immunity

  • T cells:

    • Reduction of Th17 cells (inflammatory, autoimmune-associated).

    • Expansion of regulatory T cells → improved immune tolerance.

    • Decreased CD4+ and CD8+ T-cell activation in some models.

  • B cells: RAAS inhibition affects antibody production.

:right_arrow: Cytokine Modulation

  • ACEIs and ARBs consistently lower proinflammatory cytokines (IL-6, TNF-α, IL-17).

  • They also upregulate anti-inflammatory cytokines (IL-10).

  • Net effect: shifting immune balance away from chronic inflammation.

:warning: Limitations and Challenges

  • Most data has emerged from preclinical/animal studies which means human confirmation is limited.

  • Effects may vary among different ACEIs and ARBs.

  • Long-term immune modulation risks like infection susceptibility, cancer risk alteration need careful evaluation.

Reference article: https://doi.org/10.3390/biomedicines13071779

MBH/PS

5 Likes
2

Good summary! RAAS inhibitors obviously go way beyond BP lowering, influencing innate and adaptive immunity. Great potential, but getting preclinical discoveries safely to the clinic will be the true challenge

2 Likes
3

ACEIs have shown promise in autoimmune myocarditis, colitis, and diabetic nephropathy by attenuating inflammatory cytokines.

2 Likes
4

The dual role of RAAS in both vascular health and immune regulation is fascinating. This could reshape how we approach therapy in chronic inflammatory diseases.

1 Like
5

RAAS inhibitors not only control blood pressure but also play key roles in regulating the immune system. They reduce inflammation, promote tissue repair and restore immune balance by modulating cytokines and immune cells.

1 Like
6

“I’m genuinely amazed! As a Pharm.D, it’s incredible to see how RAAS inhibitors, which we usually think of for blood pressure or kidney protection, also influence the immune system.

Learning about their effects on macrophages, T cells, and cytokines makes me appreciate the depth and interconnectedness of pharmacology.

Moments like these make me grateful for the knowledge I’ve gained and excited to keep exploring how medicines truly work in the body.

Thank you for the insight

1 Like
7

Well explained

1 Like